Adagrasib is under clinical development by Mirati Therapeutics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Adagrasib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Adagrasib (Krazati) belongs to the RAS GTPase family, an antineoplastic agent. It is formulated as film coated tablets for oral route of administration. Krazati is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Adagrasib is under development for the treatment of solid tumors including advanced colorectal cancer, squamous or non-squamous non-small cell lung cancer, colorectal cancer, breast cancer, glioblastoma multiforme, gastroesophageal (GE) junction carcinomas, ovarian cancer, endometrial cancer, bile duct cancer, metastatic pancreatic cancer and pancreatic ductal adenocarcinoma. It is administered by the oral route as a tablet. The drug candidate acts by targeting KRAS G12C mutations.
Mirati Therapeutics overview
Mirati Therapeutics is a clinical-stage oncology company that carries out the research and development of novel therapeutics to address the genetic and immunological promoters of cancer. The company product pipeline includes Adagrasib (MRTX849), an oral small molecule inhibitor of KRASG12C and MRTX1133, a potent small molecule inhibitor of the KRASG12D for the treatment of colorectal and pancreatic cancer. Mirati Therapeutics also offers MRTX1133 – pancreatic cancer and Sitravatinib – Tumor, MRTX1719 -methylthioadenosine phosphorylase (MTAP) deleted cancers and MRTX0902-solid Tumors. The company has partnered with Zai Lab, Beigene, Sanofi, Boehringer, Novartis and Bristol Myers Squibb, among others. It operates in Canada, Netherlands and the US. Mirati Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of Adagrasib’s drug-specific PTSR and LoA scores, buy the report here.